Hostname: page-component-7479d7b7d-jwnkl Total loading time: 0 Render date: 2024-07-13T20:27:48.410Z Has data issue: false hasContentIssue false

Controlled Clinical Trial of Isocarboxazid (“Marplan”) in Hospital Psychiatry

Published online by Cambridge University Press:  08 February 2018

Vasant G. Joshi*
Affiliation:
St. Francis Hospital, Haywards Heath, Sussex

Extract

A number of synthetic drugs have recently been introduced as specific antidepressants in psychiatry. Isocarboxazid (Marplan) is an analogue of iproniazid (Marsilid). Both belong to the monoamine oxidase inhibitor group of antidepressants. Isocarboxazid is said to be less toxic but of equal potency for a lesser dose than iproniazid. A controlled clinical trial of isocarboxazid was therefore undertaken to assess this drug in the treatment of depression. The results of this trial are reported in this paper together with the results of an uncontrolled trial in a further group of patients (group M) who received isocarboxazid only.

Type
Original Articles
Copyright
Copyright © Royal College of Psychiatrists, 1961 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Azima, et al., Amer. J. Psychiat., 1959, 116, (5), 453.CrossRefGoogle Scholar
2. Ayd, Frank J. Jr., Annal. N.Y. Acad. Sci., 1959, 80, (3), 734744.CrossRefGoogle Scholar
3. University of Cambridge, “Symposium on Depression (1959) Preliminary Report.” Google Scholar
4. Barton, Russell, Institutional Neurosis, 1959. Bristol: John Wright.Google Scholar
5. McGill University, Conference on Depression, Canad. Psychiat. Assn. Jl., 1959, 4 (Special Supplement).Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.